Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1675
This examiner grants 0% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18554979 | CANCER PROPHYLAXIS AND THERAPY USING TARGETED VIRAL NANOPARTICLES | Non-Final OA | The Regents of the University of California |
| 18163698 | ANTI-TFR:GAA AND ANTI-CD63:GAA INSERTION FOR TREATMENT OF POMPE DISEASE | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18331475 | CANINE CANCER VACCINE | Non-Final OA | Arizona Board of Regents on behalf of Arizona State University |
| 18278707 | MICROBIAL PRODUCTION OF POLYMERIC AMYLOID FIBERS | Non-Final OA | Washington University |
| 17913509 | TNFAIP3 AS A BIOMARKER FOR AUTOIMMUNE DISEASES | Non-Final OA | The Brigham and Women's Hospital, Inc. |
| 18214178 | METHOD FOR TREATING A PERIOHERAL ARTERIAL DISEASE | Non-Final OA | NATIONAL YANG MING CHIAO TUNG UNIVERSITY |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy